EMA Accepts Pfizer and Valneva Marketing Application for Lyme Disease Vaccine

Key Facts

In a move reflecting the acceleration of healthcare innovation to combat infectious diseases, the European Medicines Agency (EMA) has formally accepted the Marketing Authorization Application for the VLA15 vaccine. Developed jointly by Pfizer and Valneva, this candidate aims to prevent Lyme disease. The regulatory acceptance follows the successful completion of clinical trials and marks a critical milestone toward making the vaccine available in the European market.

Per market data, Pfizer (PFE) shares closed at $26.80 on August 13, 2026, with the stock trading between a day low of $26.41 and a high of $26.95. The acceptance of the application is a positive development for both companies as they advance a first-of-its-kind medical solution, although final regulatory approval remains pending further review.

Traders should watch PFE price levels relative to its $26.80 close on August 13, 2026, as the market awaits further EMA updates on the final approval timeline. In the broader macro context, recent data showing U.S. Non-Farm Payrolls falling to -23k in August may influence general risk sentiment within the pharmaceutical sector.